Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
23.76
+0.59 (+2.55%)
Streaming Delayed Price
Updated: 12:01 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arrowhead Pharma
< Previous
1
2
3
4
5
Next >
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
November 28, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
November 21, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
November 14, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 09, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
November 07, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 13, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
October 11, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
September 01, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
August 17, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
August 04, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
July 20, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 08, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
July 05, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
June 07, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 10, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
April 27, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
April 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
April 25, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
April 20, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
April 01, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
March 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
March 15, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
February 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.